INFLIXIMAB BIOSIMILAR SWITCH IS SAFE AND EFFECTIVE, IT DOES NOT HAVE MAJOR PSYCHOLOGICAL IMPLICATIONS AND DOES NOT AFFET PHARMACOKINETICS IN A LARGE COHORT OF PATIENTS WITH IBD

Giuseppe Privitera  1     Elena Melita  2     Lucia Monastero     Maria Chiara Agnitelli     Di Vincenzo Federica     Marcello Fiorani     Pierluigi Puca     Elisa Schiavoni  3     Valeria Amatucci     Daniele Napolitano     Martina Strazzeri     Laura Turchini     Franco Scaldaferri     Alessandro Armuzzi  4     Daniela Pugliese  5    
1 Università degli Studi di Milano, Milan, Italy
2 Università Cattolica del Sacro Cuore, Rome, Italy
3 Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy
4 IRCCS Humanitas Research Hospital, Milan, Italy
5 Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy

Topic
IBD

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing